Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link

Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released.

Volume 32, Number 4—April 2026

Research

Evaluation of Effectiveness of Autocidal Gravid Ovitraps for Preventing Zika Virus Infection, Puerto Rico, USA

Zachary J. MadewellComments to Author , Sandra J. Kiplagat, India Kellum, Matthew J. Lozier, Olga Lorenzi, Janice Perez-Padilla, Freddy A. Medina, Jorge L. Muñoz-Jordán, Laura E. Adams, Gabriela Paz-Bailey, Stephen H. Waterman, Roberto Barrera, and Tyler M. Sharp
Author affiliation: Centers for Disease Control and Prevention, San Juan, Puerto Rico, USA (Z.J. Madewell, S.J. Kiplagat, I. Kellum, M.J. Lozier, O. Lorenzi, J. Perez-Padilla, F.A. Medina, J.-L. Muñoz-Jordán, L.E. Adams, G. Paz-Bailey, S.H. Waterman, R. Barrera, T.M. Sharp); US Public Health Service Commissioned Corps, Rockville, Maryland, USA (L.E. Adams, T.M. Sharp)

Main Article

Table 1

Characteristics of participants in an evaluation of effectiveness of autocidal gravid ovitraps for preventing Zika virus infection, Puerto Rico, USA*

Characteristics Total, n = 271 Participant data
p value†
Intervention, n = 136 Nonintervention, n = 135
Age group, y, n = 267 0.283
<20 18 (6.7) 9 (6.7) 9 (6.8)
20–39 31 (11.6) 19 (14.2) 12 (9.0)
40–59 86 (32.2) 47 (35.1) 39 (29.3)
>60
132 (49.4)
59 (44.0)
73 (54.9)

Median age, y (IQR)
59 (46–69)
59 (43–69)
60 (49–69)
0.324
Sex 0.242
F 165 (60.9) 88 (64.7) 77 (57.0)
M
106 (39.1)
48 (35.3)
58 (43.0)

Years in community, n = 269 0.244
0–19 104 (38.7) 56 (41.2) 48 (36.1)
20–39 116 (43.1) 52 (38.2) 64 (48.1)
>40
49 (18.2)
28 (20.6)
21 (15.8)

Median years (IQR) in community, n = 269
24 (12–35)
21 (13–35)
29 (12–34)
0.307
Acute illness with rash, fever, or joint pain since November 2015, n = 270 0.271
Y 58 (21.5) 25 (18.4) 33 (24.6)
N
212 (78.5)
111 (81.6)
101 (75.4)

Household characteristics
No. persons in household 0.516
1 60 (22.1) 30 (22.1) 30 (22.2)
2 101 (37.3) 47 (34.6) 54 (40.0)
3 52 (19.2) 25 (18.4) 27 (20.0)
>4 58 (21.4) 34 (25.0) 24 (17.8)
Median no. (IQR) persons in household 2 (2–3) 2 (2–3) 2 (2–3) 0.454
No. children <5 years of age 0.081
0 250 (92.3) 121 (89.0) 129 (95.6)
1 17 (6.3) 13 (9.6) 4 (3.0)
2 4 (1.5) 2 (1.5) 2 (1.5)
Annual household income, USD, n = 238 0.059
<25,000 173 (72.7) 88 (73.3) 85 (72.0)
26,000–50,000 46 (19.3) 18 (15.0) 28 (23.7)
51,000–75,000 16 (6.7) 11 (9.2) 5 (4.2)
>76,000 3 (1.3) 3 (2.5) 0 (0.0)
Dwelling type 0.393
One-story house 248 (91.5) 122 (89.7) 126 (93.3)
Two-story house 23 (8.5) 14 (10.3) 9 (6.7)
No. screened windows/doors, n = 270 0.789
1 139 (51.5) 70 (51.9) 69 (51.1)
2 87 (32.2) 45 (33.3) 42 (31.1)
3 44 (16.3) 20 (14.8) 24 (17.8)
Air conditioning use 0.312
In all rooms 42 (15.5) 18 (13.2) 24 (17.8)
Only in bedroom at night 140 (51.7) 68 (50.0) 72 (53.3)
None 89 (32.8) 50 (36.8) 39 (28.9)
Frequency of open windows/doors 0.496
Always 96 (35.4) 46 (33.8) 50 (37.0)
Only during the day 116 (42.8) 63 (46.3) 53 (39.3)
Only at night 7 (2.6) 2 (1.5) 5 (3.7)
Never
52 (19.2)
25 (18.4)
27 (20.0)

Mosquito exposure
Weekly hours at home 0.827
<24 19 (7.0) 9 (6.6) 10 (7.4)
25–60 91 (33.6) 48 (35.3) 43 (31.9)
61–84 161 (59.4) 79 (58.1) 82 (60.7)
Median weekly hours (IQR) at home 73 (42–84) 72 (42–84) 74 (44–84) 0.536

*Values are no. (%) except as indicated. Intervention communities had autocidal gravid ovitraps installed; nonintervention communities did not have traps during March–May 2017, when the Zika virus epidemic was ongoing. IQR, interquartile range. †χ2 test was used for comparison of percentages, Fisher exact test was for comparison of categories with >1 value <5, and Mann-Whitney U test was used for medians.

Main Article

Page created: March 04, 2026
Page updated: April 01, 2026
Page reviewed: April 01, 2026
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external